ArticleClinical cancer research : an official journal of the American Association for Cancer Research2025

Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild-type Acute Myeloid Leukemias.

Weiguo Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.